Aptevo Says Mipletamig Combination Enabled 21% of AML Patients to Reach Stem Cell Transplant
The report describes a treatment outcome in frontline AML patients; no broader market impact is specified.
The report describes a treatment outcome in frontline AML patients; no broader market impact is specified.